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Abstract
Background
Short telomere length independently predicts mortality in patients with coronary heart dis-
ease. Whether 5-year change in telomere length predicts subsequent mortality in patients
with coronary heart disease has not been evaluated.
Methods
In a prospective cohort study of 608 individuals with stable coronary artery disease, we
measured leukocyte telomere length at baseline and after five years of follow-up. We
divided the sample into tertiles of telomere change: shortened, maintained or lengthened.
We used Cox survival models to evaluate 5-year change in telomere length as a predictor
of mortality.
Results
During an average of 4.2 years follow-up, there were 149 deaths. Change in telomere
length was inversely predictive of all-cause mortality. Using the continuous variable of
telomere length change, each standard deviation (325 base pair) greater increase in telo-
mere length was associated with a 24% reduction in mortality (HR 0.76, 95% CI 0.61–
0.94; p = 0.01), adjusted for age, sex, waist to hip ratio, exercise capacity, LV ejection
fraction, serum creatinine, and year 5 telomere length. Mortality occurred in 39% (79/203)
of patients who experienced telomere shortening, 22% (45/203) of patients whose telo-
mere length was maintained, and 12% (25/202) of patients who experienced telomere
lengthening (p<0.001). As compared with patients whose telomere length was
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maintained, those who experienced telomere lengthening were 56% less likely to die (HR
0.44, 95% CI, 0.23–0.87).
Conclusions
In patients with coronary heart disease, an increase in leukocyte telomere length over 5
years is associated with decreased mortality.
Significance
Leukocyte telomere length may serve as a marker of biological aging and predictor of mortality.
Whether 5-year change in telomere length predicts subsequent mortality has not been evalu-
ated. In a longitudinal study of 608 patients who were followed for 9.2 years, we found that leu-
kocyte telomere shortening during the first five years was an independent predictor of
mortality during the subsequent 4.2 years. Every 325 base pair increase in telomere length dur-
ing the first 5 years was associated with 24% lower mortality during follow-up. This is the first
study to show that 5-year change in telomere length predicts subsequent mortality.
Introduction
Telomeres are tandemDNA repeat sequences at the ends of eukaryotic chromosomes that pro-
tect genomic information during mitosis[1]. During cell division, DNA polymerase cannot
fully replicate the 3’ end of linear DNA, resulting in a progressive loss of telomere repeats[2].
After a critical degree of telomere shortening, cells can undergo transcriptional profile alter-
ations, lose the ability to replicate and cease dividing (cellular senescence), and may undergo
apoptosis[3]. Human telomere length is influenced by both genetic and environmental factors
[4]. These observations have led to an increasing interest in telomere maintenance as the possi-
ble basis for a “biological clock,” as initially proposed on theoretical grounds by Olonikov in
1973, which integrates the cumulative lifetime burden of genetic factors and environmental
stressors independently of chronological age[5].
The strongest evidence that cellular aging, as represented by short telomeres, might be asso-
ciated with human aging in populations (as well as in carriers of mutations known to directly
impair telomere maintenance [6] has primarily been derived from cross sectional studies. Prior
studies have shown an independent association between short telomere length and cardiovas-
cular events, including myocardial infarction[7], congestive heart failure[8], stroke[9] and
death[10, 11]. However, little is known about the dynamic change and regulation of telomere
length over time, and their consequences. One longitudinal study of 236 healthy men found
that leukocyte telomere length shortening was a predictor of subsequent cardiovascularmortal-
ity[12]. However, no studies have examined whether change in leukocyte telomere length pre-
dicts mortality in patients with coronary artery disease.
We sought to investigate the association between change in leukocyte telomere length over
5 years and subsequent mortality in a prospective cohort study of in 608 patients with stable
coronary heart disease (CHD).
Telomere Shortening and Mortality
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Methods
Participants
The Heart and Soul Study is a prospective cohort study investigating the influence of psychoso-
cial factors on cardiovascular events in patients with stable coronary artery disease. The enroll-
ment process and methods have been described in detail previously [11] [13] [14]. Eligible
participants were recruited from outpatient clinics in the San Francisco Bay Area if they met at
least one of the following inclusion criteria: 1) history of myocardial infarction, 2) angiographic
evidence of at least 50% stenosis by area in a least one coronary artery, 3) evidence of exercise-
induced ischemia by treadmill electrocardiogramor stress nuclear perfusion imaging, or 4) his-
tory of coronary revascularization. Individuals were excluded if they had a history of myocar-
dial infarction in the past 6 months, deemed themselves unable to walk 1 block, or if they were
planning to move out of the local area within 3 years.
Between September 2000 and December 2002, a total of 1024 participants enrolled in the
study. Of these, 954 provided DNA samples for analysis at the baseline visit, and 608 also pro-
videdDNA samples after 5 years of follow-up. The study protocol was approved by the Com-
mittee on Human Research at the University of California, San Francisco, and all participants
provided written informed consent.
Telomere Length Assay
Blood samples collected from participants at baseline and after 5 years of follow-up were sub-
jected to density gradient centrifugation to yield a buffy coat preparation containing peripheral
blood leukocytes and stored at -70C. Genomic DNA was isolated according to standard proce-
dures using theWizard Genomic DNA PurificationKit (Promega Corp, MadisonWI). After
verifying the integrity and purity of DNA, samples were diluted in 96-well microtiter source
plates to a fixed concentration of 3 ng/ul. Relative mean telomere length was measured from
DNA by a quantitative polymerase chain reaction (qPCR) assay that compares mean telomere
repeat sequence copy number (T) to a reference single-copy gene copy number (S) in each
sample as previously described and validated by comparison with Southern blot terminal
restriction fragment (TRF) analysis[15]. Standard curveswere derived from serially diluted ref-
erence DNA. The T/S ratio was determined from the average quantity of reference DNA found
to match with each experimental sample for the copy number of the targeted template (the
number of telomere repeats for T and the number of beta-globin gene copies for S). Measure-
ments of baseline and 5-year DNA were performed at the same time; both baseline and 5 year
samples from the same subjects were run on the same plate.
The primers for the telomere qPCR were tel1b [5’-CGGTTT(GTTTGG)5GTT-3’]and
tel2b [5’-GGCTTG(CCTTAC)5CCT-3’], each used at a final concentration
of 900 nM. Human beta-globinqPCR primerswere: hbg1 [5’-GCTTCTGACACA
ACTGTGTTCACTAGC-3’],used at a final concentrationof 300 nM, and
hbg2 [5’-CACCAACTTCATCCACGTTCACC-3’], used at a final concentration of 700 nM.
The final reactionmix was: 20 mMTris-HCl, pH 8.4; 50 mMKCl; 200 nM each dNTP; 1%
DMSO; 0.4xSybr Green I; 44 ng Escherichia Coli DNA; 0.8 U Platinum Taq DNA polymerase
(Invitrogen) per 11 ul reaction; 10 ng genomic DNA. All PCRs were carried out on a Roche
Lightcycler 480 real-time PCRmachine (Roche Applied Science, Indianapolis, IN).
To control for inter-assay variability, eight control DNA samples were included in each
run. The T/S ratio of each control DNA was divided by the average T/S ratio for the same
DNA from each run to obtain a normalizing factor. The average normalizing factor was then
used to adjust the participant DNA measurements to obtain the final T/S ratios in each batch.
Telomere Shortening and Mortality
PLOS ONE | DOI:10.1371/journal.pone.0160748 October 26, 2016 3 / 12
The coefficient of variability for the eight control samples across all batches was 6%. The T/S
ratio at baseline and follow-up for each participant was measured in duplicate. When the
duplicate T/S ratio and the initial value varied by more than 7%, the sample was run for a
third time, and the two closest values were used. Approximately 15% of samples required
assay in triplicate. Using this method, the inter-assay coefficient of variability for telomere
length measurement was 3.7% (equivalent to 0.20 kilobases with respect to the baseline
mean). The intra-assay coefficient of variability was 2.5% (equivalent to 0.13 kilobases with
respect to the baseline mean).
To determine the conversion factor for the calculation of approximate base pair telomere
length from T/S ratio, the above method was used to determine the T/S ratios, relative to the
same reference DNA, for a set of genomic DNA samples from the human fibroblast primary
cell line IMR90 at different population doublings, as well as with the telomerase protein sub-
unit gene (hTERT) transfected into a lentiviral construct. The average T/S ratio for the Heart
and Soul Study samples was lower than the range of T/S obtained with the IMR90 cell samples.
The mean TRF length from the IMR90 samples was determined using Southern blot analysis,
and the slope of the plot of mean TRF length versus T/S served as the conversion factor for cal-
culation of telomere length in base pairs from the T/S ratio (S1 Fig). The equation for conver-
sion from T/S ratio to base pairs for this study was base pairs = 3274+2413(T/S).
Other Measurements
All covariates were assessed at the 5-year examination. As previously described [11] [13] [14],
demographics, age, sex, self-reported ethnicity, education, and income level were obtained by
questionnaire. Cardiovascular co-morbidities and prior medical history were determined by
self-report. Participants were weighed and measured without shoes. Bodymass index was cal-
culated as weight in kilograms divided by height in squared meters. Waist-to-hip ratio was cal-
culated as waist circumference divided by hip circumference. Exercise capacity was measured
at peak exertion during a symptom-limited exercise-treadmill stress test as previously
described[13].
All patients underwent complete resting 2-dimensional echocardiography and Doppler
examination using an Acuson Sequoia ultrasound system (SiemensMedical Solutions, Moun-
tain View, CA) with a 3.5-MHz transducer. The left ventricular ejection fraction (LVEF) was
calculated as (end diastolic volume—end systolic volume)/end diastolic volume. Fasting venous
blood samples were obtained to measure serum biomarkers. HDL- and LDL-cholesterol levels
and C-reactive protein (CRP) were measured in a clinical laboratory setting.
Mortality
Following the 5-year examination, we conducted annual telephone interviewswith participants
or their proxies regarding recent emergency room visits, hospitalization or death. For any
reported event, medical records, death certificates, and coroner’s reports were obtained and
reviewed by 2 independent and blinded adjudicators. If the adjudicators agreed on the outcome
classification, their classification was binding. If they disagreed, a third blinded adjudicator
reviewed the event and determined the outcome classification.
All-cause mortality was determined by review of death certificates. The outcome variable
was time from the 5-year examination to death or last follow-up. The mean length of follow-up
after the 5-year examination was 4.2 ± 1.4 years (total duration of follow-up for Heart and Soul
Study was 9.0 ± 1.4 years). Ascertainment of outcomes was achieved in 100% of participants.
Telomere Shortening and Mortality
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Statistical Analyses
Baseline and follow-up telomere lengths were normally distributed. To evaluate telomere
change as a continuous variable, we regressed 5-year change on baseline telomere length, saved
the residual, and evaluated the residual as the independent variable. To explore the relationship
of this continuous variable with mortality, we graphed findings using deciles. To evaluate telo-
mere length categorically, defined by trajectory, as done previously[12, 14] we divided leuko-
cyte telomere trajectory into tertiles and categorized participants as shortened (lowest tertile),
maintained (middle tertile) or lengthened (highest tertile). This resulted in the maintenance
group including zero change, from -167 to +113, the shortened group ranged from -1012 to
-169bp, and the lengthened group ranged from +114 to +1245bp.
Differences in participant characteristics were compared with the use of ANOVA for con-
tinuous variables and the chi-squared test for dichotomous variables, using the categorical
trajectory variable. We generated a Kaplan Meier figure and used a log rank test to compare
survival across the 3 categories. We then used Cox proportional hazard models to examine
the association between telomere trajectory and all-cause mortality, adjusted for patient char-
acteristics that differed between the trajectory groups (at p<0.10). Covariates were added
sequentially in multivariable models to assess the incremental attenuation attributable to
each adjustment step. Telomere trajectorywas evaluated both as a categorical variable and as
a continuous variable. To explore potential effect modifiers, we tested for interactions of telo-
mere change with age, sex, and smoking in the final multivariable-adjusted model (all
nonsignificant).
Since we have previously demonstrated that short baseline telomere length is a strong pre-
dictor of mortality[11], we sought to evaluate the incremental prognostic value of 5-year
change in telomere length vs. a one-timemeasurement of telomere length. To determine the
incremental prognostic value of calculating change in telomere length during the previous 5
years (vs. a single measure of telomere length at the 5-year exam), we calculated C statistics for
models predictingmortality that were adjusted for each of these variables separately and esti-
mated 95% confidence intervals from 5,000 bootstrap samples with replacement. Statistical
analysis was performed using Intercooled Stata, version 9.2 (Stata Corp, College Station, TX).
Results
The characteristics of the study population categorized by 5-year change in telomere length are
shown in Table 1. After dividing the sample into tertiles, there were a total of 203 participants
who experienced telomere shortening, 203 whomaintained their telomere length and 202 who
experienced telomere lengthening. As compared with participants who experienced telomere
lengthening, those with telomere shortening were older and more likely to be male. Partici-
pants with telomere shortening also had higher waist to hip ratio, lower treadmill exercise
capacity, higher LV ejection fraction, and worse kidney function. Baseline telomere length did
not differ across the 3 categories, but those who experienced5-year telomere shortening had
shorter 5-year telomere length than those who experienced 5-year telomere lengthening. There
were no differences in ethnicity, education, income, bodymass index, or comorbidities across
categories of telomere trajectory.
During a mean follow-up of 4.2 ± 1.4 years, there were 149 deaths. Telomere change was
inversely associated with mortality (Fig 1, Table 2). Mortality ranged from 46% in the lowest
decile to 12% in the highest decile of change. In an unadjusted analysis, each standard deviation
(325 base pairs) increase in telomere change was associated with a 36% lower risk of death
(Table 3, HR 0.64, 95% CI, 0.54–0.76; p<0.001). After adjustment for age, sex, waist to hip
ratio, exercise capacity, LV ejection fraction, serum creatinine, and year 5 telomere length, each
Telomere Shortening and Mortality
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SD increase in telomere change remained associated with a 24% lower risk of death (HR 0.76,
95% CI 0.61–0.94; p = 0.01).
Mortality occurred in 39% (79/203) of patients who experienced telomere shortening, 22%
(45/203) of patients whose telomere length was maintained, and 12% (25/202) of patients who
experienced telomere lengthening (p<0.001). As compared with patients who maintained telo-
mere length, patients who experienced telomere lengthening had a 56% lower risk of mortality
(Fig 2, Table 4, adjusted HR 0.44, 95% CI, 0.23–0.87).Mortality was higher in patients with
telomere shortening (vs. maintenance), but this association was not statistically significant (HR
1.32, 95% CI, 0.84–2.08; p = 0.23). We found no evidence for an interaction of telomere cate-
gory with age, sex or smoking (all p values for interaction> 0.05).
We calculated C statistics to compare the prognostic value of 5-year telomere change vs. a
one-timemeasurement of telomere length for predictingmortality. After adjustment for age,
sex, waist to hip ratio, exercise capacity, LV ejection fraction, and creatinine, the C statistic was
0.73 for a model with telomere change alone, 0.73 for a one-timemeasurement of telomere
length (at year 5), and 0.69 for a model with both 5-year telomere change and a one-timemea-
surement of telomere length (at year 5). There was no statistical difference between these C
statistics.
Table 1. Characteristics of participants by change in telomere length during the previous 5 years*.
5-Year Change in Leukocyte Telomere Length
Variable Shortened Maintained Lengthened P value
N = 203 N = 203 N = 202
Range (base pairs) -1012 to -169 -167 to 113 114 to 1245
Average base pairs/year -202 to -34 -33 to 22.6 22.8 to 249
Age, yrs 69 ± 9.5 66 ± 9.9 63 ± 10.2 <0.001
Male 184 (91) 167 (82) 148 (73) <0.001
White 125 (62) 124 (61) 113 (56) 0.249
Income <$20,000 84 (42) 93 (46) 96 (48) 0.230
High school education 174 (86) 176 (87) 184 (91) 0.125
BMI, kg/m2 28.3 ± 4.6 28.9 ± 5.4 28.6 ± 5.4 0.499
Waist-hip ratio 0.98 ± 0.08 0.94 ± 0.08 0.94 ± 0.08 <0.001
Current smoking 34 (17) 31 (15) 36 (18) 0.756
History of HTN 144 (71) 144 (71) 137 (68) 0.496
History of MI 111 (55) 100 (49) 106 (52) 0.582
History of Stroke 33 (16) 20 (10) 22 (11) 0.100
History of HF 35 (17) 27 (13) 28 (14) 0.370
History of DM 52 (26) 48 (24) 46 (23) 0.504
Systolic blood pressure, mmHg 132 ± 19 133 ± 21 133.05 ± 20 0.630
Exercise capacity, METS 7.49 ± 2.96 8.10 ± 3.41 8.32 ± 3.23 0.012
LV ejection fraction 63 ± 8 63 ± 10 62 ± 9 0.062
HDL, mg/dl 45 ± 12 46 ± 15 47 ± 15 0.109
LDL, mg/dl 102 ± 33 108 ± 36 102 ± 31 0.916
C-reactive protein, mg/L 3.2 ± 4.0 4.2 ± 7.1 4.3 ± 8.2 0.100
Serum creatinine 1.2 ± 0.8 1.0 ± 0.4 1.1 ± 0.5 0.077
Baseline telomere length (bp) 5562 ± 577 5390 ± 523 5536 ± 465 0.609
5-year telomere length (bp) 4971 ± 204 5230 ± 165 5661 ± 260 <0.001
*Number (%) or mean ± SD
doi:10.1371/journal.pone.0160748.t001
Telomere Shortening and Mortality
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Discussion
Telomere maintenance has a significant impact on the ability of cells to continue dividing[16].
However, previous studies evaluating a single measurement of leukocyte telomere length as a
predictor of mortality have yieldedmixed results[17, 18]. We hypothesized that change in telo-
mere length, when examined several years apart, may be a more robust indicator of telomere
health (and a stronger predictor of mortality) than a one-timemeasurement. In this longitudi-
nal study of 608 patients with stable coronary artery disease who were followed for 9.2 years,
we found that change in leukocyte telomere length during the first five years was an indepen-
dent predictor of mortality during the subsequent 4.2 years. Each 325 base pair increase in telo-
mere length during the first 5 years was associated with 24% lower mortality during the
Fig 1. Mortality by decile of 5-year change in telomere length (p for trend <0.001).
doi:10.1371/journal.pone.0160748.g001
Table 2. Mortality by decile of 5-year telomere change.
Decile Range (base pairs) Average base pairs/year Number of study participants Number (%)who died
1 -1012 to -371 -202 to -74 61 28 (46%)
2 -370 to -275 -74 to -55 61 22 (36%)
3 -274 to -184 -55 to -37 61 22 (36%)
4 -184 to -102 -37 to -20 61 16 (26%)
5 -99 to -32 -20 to -6 60 20 (33%)
6 -32 to 54 -6 to 11 61 11 (18%)
7 56 to 148 11 to 30 61 7 (11%)
8 148 to 268 30 to 54 61 8 (13%)
9 279 to 429 56 to 86 61 8 (13%)
10 430 to 1245 86 to 249 60 7 (12%)
doi:10.1371/journal.pone.0160748.t002
Telomere Shortening and Mortality
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subsequent 4.2 years. This observation raises the possibility that change in telomere length may
influencemortality and/or serve as a biomarker of cellular aging.
The mechanism by which leukocyte telomere shortening and mortality are linked is not
well understood. Traditional clinical risk factors do not seem to explain our finding, given the
similarity between patients across a broad array of demographic, clinical, and biochemical vari-
ables. Biochemical stress, mediated via oxidative stress and inflammation, may provide a
potential link between telomere shortening and mortality, as it is a known driver of telomere
shortening, cardiovascular disease, and organismal aging[19, 20]. Oxidative stress has a direct
negative effect on telomere length maintenance, both through inhibition of telomerase activity
Table 3. Association between 5-year telomere change [entered as a continuous variable, per stan-
dard deviation (325 base pair) increase] and mortality in 608 study participants.
Hazard Ratio (95% CI) P value
Unadjusted 0.64 (0.54–0.76) <0.001
Model 1 0.74 (0.61–0.88) 0.001
Model 2 0.77 (0.64–0.91) 0.003
Model 3 0.76 (0.61–0.94) 0.01
Model 1 = adjusted for age, sex
Model 2 = adjusted for age, sex, HDL, and smoking
Model 3 = adjusted for age, sex, waist to hip ratio, exercise capacity, LV ejection fraction, serum creatinine,
and year 5 telomere length
doi:10.1371/journal.pone.0160748.t003
Fig 2. Survival in 608 patients with coronary heart disease, stratified by change in telomere length during
the previous 5 years (overall log rank test p<0.0001).
doi:10.1371/journal.pone.0160748.g002
Telomere Shortening and Mortality
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[21] and direct damage to GGG triplets in telomeric DNA[22]. Several diseases such as cardio-
vascular disease and malignancy have been linked to chronic oxidative stress and accelerated
telomere shortening[23, 24].
Another potential mechanism for the link between telomere shortening and mortality may
be in the activity of the enzyme telomerase. Lin et al found that changes in leukocyte telomere
length were associated with telomerase activity [25]. Change in telomere length is regulated by
many factors, including the activity of telomerase, a cellular ribonucleoprotein reverse tran-
scriptase enzyme that maintains telomeric DNA, and cell division capacity. Both in vitro and
human studies have shown that leukocyte telomeres can lengthen[26] [14]. Telomerase coun-
teracts telomere shortening by addition of DNA nucleotides onto telomeres[27, 28]. In patients
with cardiovascular disease, telomerase is crucial for cardiovascular cell functioning[29] and its
deficiencyhas been linked to cardiovascular risk factors in vivo[30].
In addition, leukocyte telomere shortening may contribute directly to disease and mortality.
As discussed, short telomeres lead to cell senescence and death [31, 32]. Senescent cells secrete
pro-inflammatory cytokines[33], which can contribute to a pro-inflammatorymilieu and
resultant cellular damage.
Among the strengths of the present study are the detailedmeasurement of multiple poten-
tial confounding variables including comorbid conditions and cardiac disease severity. This
study design allowed us to prospectively investigate the prognostic value of change in leukocyte
telomere length in a large cohort of comprehensively phenotyped patients with CAD. However,
several limitations must be considered when interpreting our results. First, our participants
were mostly urbanmen, all with coronary artery disease, so our results may not generalize to
other populations. Second, due to long term storage of blood samples, we were unable to mea-
sure biomarkers of oxidative stress or telomerase activity. Third, the question of whether telo-
mere shortening is merely an epiphenomenon, or whether it plays an active role in mortality,
cannot be answered on the basis of our results. However, the marked lack of variation between
groups in terms of many clinical and laboratory factors suggests that telomere shortening is an
independent risk factor not captured by traditional models of risk. Finally, as with any repeated
measurement of a continuous variable, the possibility of regression to the mean must be con-
sidered. However, this is very unlikely because patients were not selected on the basis of base-
line telomere length, and the measurements of year 5 telomere length had less variance than
the baselinemeasurements [14].
In summary, we report that leukocyte telomere shortening over 5 years in a cohort of indi-
viduals with stable coronary artery disease is associated with subsequent mortality, indepen-
dent of existing cardiac risk factors. Further studies should be aimed at investigating the
Table 4. Association between category of 5-year telomere trajectory and mortality.
Shortened Maintained Lengthened
N = 203 N = 203 N = 202
HR (95% CI) P value HR (95% CI) P value
Unadjusted 1.62 (1.12–2.34) 0.01 reference 0.53 (0.33–0.87) 0.01
Model 1 1.52 (0.99–2.32) 0.05 0.50 (0.28–0.90) 0.02
Model 2 1.33 (0.87–2.04) 0.19 0.59 (0.33–1.07) 0.09
Model 3 1.32 (0.84–2.08) 0.23 0.44 (0.23–0.87) 0.02
Model 1 = adjusted for Y5 telomere length
Model 2 = adjusted for age, sex and Y5 telomere length
Model 3 = adjusted for age, sex, year 5 telomere length, waist to hip ratio, exercise capacity, LV ejection fraction and creatinine
doi:10.1371/journal.pone.0160748.t004
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mechanisms and significance of the association between change in telomere length and mortal-
ity in patients with stable CAD, as well as investigating whether these results can be replicated
in other cohorts of patients.
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